IncludeHealth, a digital musculoskeletal (MSK) health company, today announced a partnership with Yale New Haven Health System (YNHHS) to transform care for patients with musculoskeletal health conditions.
IncludeHealth to Provide Musculoskeletal Care in Patients’ Homes in Partnership with Yale New Haven Health
13 déc. 2022 04h00 HE | IncludeHealth
CINCINNATI, OHIO, Dec. 13, 2022 (GLOBE NEWSWIRE) -- IncludeHealth, a digital musculoskeletal (MSK) health company, today announced a partnership with Yale New Haven Health System (YNHHS) to...
Algernon Logo 1.png
Algernon Pharmaceuticals Enters into a Clinical Trial Agreement with Yale University for a DMT Phase 2 Depression Study
24 oct. 2022 07h00 HE | Algernon Pharmaceuticals
VANCOUVER, British Columbia, Oct. 24, 2022 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF) a clinical stage pharmaceutical...
Researchers Investig
Researchers Investigate Nature’s Smallest “Social Cheaters”
14 sept. 2022 12h30 HE | Burroughs Wellcome Fund
Research Triangle Park, N.C., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Being a member of a community often requires sacrifice. Species from across the animal kingdom have been shown to cooperate with...
Picture3.jpg
Yale’s Department of Psychiatry Chair to Join Clearmind Medicine
21 juin 2022 09h00 HE | Clearmind Medicine Inc.
Dr. John H. Krystal, world-leading expert in alcoholism and depression, will serve on scientific advisory board VANCOUVER, June 21, 2022 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (CSE: CMND,...
Denver Grand Re-Opening
Blue Federal Credit Union Announces Grand Re-Opening of Denver Location
21 févr. 2022 08h30 HE | Blue Federal Credit Union
Denver, Colorado, Feb. 21, 2022 (GLOBE NEWSWIRE) -- Blue Federal Credit Union is excited to announce the grand re-opening of its south Denver branch located at 6460 East Yale Avenue. The opening...
Xanadu Logo.jpg
Xanadu Bio Obtains Licenses and Options to Novel Platform Technologies from Yale University to Develop an Intranasal SARS CoV-2 mRNA Vaccine Booster Aimed at Inducing Local Mucosal Immunity to Prevent SARS CoV-2 Infection and Virus Transmission
08 févr. 2022 07h30 HE | Xanadu Bio
~ Company licenses PACE, a next generation polymeric nanoparticle delivery platform, and options intranasal PACE/Spike mRNA and Spike recombinant protein vaccine boosters for the treatment of...
logo-brainhq-hi-res-hori.png
Study: New Intervention Helps with Alcohol-related Cognitive Impairment
14 déc. 2020 08h00 HE | Posit Science
SAN FRANCISCO, Dec. 14, 2020 (GLOBE NEWSWIRE) -- Researchers at Yale published positive results from a pilot study of a novel combination therapy in patients with Mild Cognitive Impairment related...
Logo_final_color.png
Cybrexa Therapeutics Expands Scientific Advisory Board With Appointment of Leader in Lung Cancer Research Roy Herbst, M.D., Ph.D.
03 août 2020 07h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Logo_final_color.png
Cybrexa Therapeutics to Present First Efficacy and Safety Data From Its Lead Program CBX-12 and Initial Data From CBX-13 at the American Association for Cancer Research (AACR) Virtual Annual Meeting II
15 mai 2020 04h00 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., May 15, 2020 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex™ tumor targeting...
Logo_final_color.png
Cybrexa Therapeutics Announces Expansion of Its Anticancer Pipeline
09 déc. 2019 08h30 HE | Cybrexa Therapeutics
NEW HAVEN, Conn., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, a biotechnology company developing a new class of cancer therapeutics through its alphalex™ tumor targeting platform, today...